A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
عنوان الدراسة
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
داعم الدراسة
Novartis
دواء الدراسة
Ruxolitinib (INC424) (Jakavi)
رقم بروتوكول الدراسة
CINC424C2301
حالة الدراسة
Ongoing
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.